GRI Bio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GRI Nasdaq 2830 www.gribio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GRI Bio, Inc.

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions - Apr 8th, 2026 6:30 am
How The Grainger (LSE:GRI) Investment Story Is Evolving As The Narrative Holds Steady - Apr 4th, 2026 10:11 am
3 Undervalued Small Caps In Global With Recent Insider Activity - Apr 2nd, 2026 3:40 am
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment - Feb 17th, 2026 7:15 am
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026 - Feb 9th, 2026 9:30 am
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Feb 5th, 2026 7:15 am
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights - Feb 4th, 2026 6:45 am
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF - Jan 28th, 2026 6:45 am
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures - Jan 26th, 2026 6:30 am
GRI Bio Announces Reverse Stock Split - Jan 21st, 2026 2:01 pm
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 - Jan 8th, 2026 6:00 am
GRI Bio Announces Closing of $8.0 Million Public Offering - Dec 12th, 2025 2:05 pm
GRI Bio Announces Pricing of $8,000,000 Million Public Offering - Dec 11th, 2025 7:15 am
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Dec 10th, 2025 2:05 pm
Sector Update: Health Care Stocks Climb Late Afternoon - Sep 11th, 2025 1:49 pm
Sector Update: Health Care Stocks Higher Thursday Afternoon - Sep 11th, 2025 11:29 am
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Sep 11th, 2025 6:45 am
GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 3rd, 2025 7:00 am
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 - Aug 15th, 2025 8:00 am
GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - Aug 14th, 2025 7:15 am